NEW YORK, March 30, 2017 /PRNewswire/ --
A report published by Grand View Research, Inc. projects that the global medical cannabis market will reach a value of USD 55.8 billion by 2025. The growing number of states and countries getting approval for using it in therapeutic applications is one of the crucial factors driving the demand over the coming few years. The increasing interest amongst the academic researchers and healthcare providers regarding the therapeutic uses of cannabis is among the significant factors which are expected to push the market to new highs over the coming years. ChineseInvestors.com Inc. (OTC: CIIX), Mentor Capital, Inc. (OTC: MNTR), Lexaria Bioscience Corp. (OTC: LXRP), Kush Bottles Inc. (OTC: KSHB), Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP)
The Arcview Group pointed out that in the relatively mature Colorado market, there are now hundreds of branded products on shelves. The top five brands accounted for nearly half of all edible sales. "The explosion in the number of brands and products is dizzying," said Arcview Editor-in-Chief Tom Adams. "When the #1 concentrate brand in CO grows 84 percent but its market share percentage remains constant it becomes clear we are in a remarkable business boom. It reminds me of 1998, when Google was just one of dozens of search engines, or 1988 when Blockbuster was just one of dozens of video store chains; future market leaders are just now being launched."
ChineseInvestors.com Inc. (OTCQB: CIIX) is a premier financial information website for Chinese-speaking investors. Earlier today the company announced that, "its investment in Breakwater MB, LLC, a cannabis-focused investment and consulting company. Building on the success that CIIX enjoyed through its investment in early-stage firm Medicine Man Technologies, the Company is pleased to announce another strategic investment in the cannabis industry.
Breakwater MB was formed by CIIX board member and former CFO Paul Dickman as a means to invest capital in and provide consulting services to private, cannabis-focused companies as they transition into the public market. The invested capital will primarily be used to cover the costs of becoming a publicly traded company, a strategy CIIX expects will provide significant investment appreciation and opportunity for liquidity. All opportunities will be evaluated by the investment committee comprised of CIIX CEO Warren Wang, Medicine Man Technologies (OTCQB: MDCL) CEO Andy Williams, and Paul Dickman, the CFO of Medicine Man and managing member of Breakwater MB.
"With the gradual opening up of the cannabis industry in the U.S., the potential development of cannabis companies will be huge in the future. U.S. states will continue to issue cannabis licenses to applicants, while licensed cannabis stores will continue to have long queues of consumers. As a result, I believe that CIIX will recognize generous returns from this investment in a cannabis-focused investment and consulting company," says Wang.
In addition, Mr. Wang stated, "Breakwater MB is managed by Mr. Dickman, who has extensive experience in the financial and capital markets. He served as the CFO of CIIX from July 2010 - October 2016 and has served as the CFO for companies in a variety of industries both domestically and abroad. As a licensed CPA since 2005, Mr. Dickman has successfully taken numerous companies through multiple fund raising transactions, including private placements of debt and equity and IPOs. Based on his rich experience in the financial market and unique investment vision, I am confident in this mutually beneficial cooperation."
Mentor Capital, Inc. (OTCQB: MNTR) makes medical marijuana and cannabis related acquisitions and funding to established founders as a publicly traded operating company with a $23 million capital structure. The company recently announced that it has closed and paid in cash and stock a $1.0 million multi-faceted financing program for G FarmaLabs Limited. The initial Mentor financing is structured to provide funding for real estate and working capital. G Farma has also been provided Mentor public shares to participate in any potential upside that may or may not occur on account of the G Farma relationship with Mentor.
Lexaria Bioscience Corp. (OTCQB: LXRP) is a food biosciences company with a proprietary technology for improved delivery of bioactive compounds. The Company's lipophilic enhancement technology has been shown to enhance the bioavailability of orally ingested cannabinoids, while also improving taste. This technology promotes healthy ingestion methods, lower overall dosing and higher effectiveness in active molecule delivery. On March 22nd the company announced the introduction of the TurboCBD™ brand of technologically enhanced, high absorption full spectrum hemp oil capsules. Lexaria's TurboCBD™ capsules are specially formulated with the finest American Ginseng and Ginkgo Biloba for support of enhanced focus and memory, and reduced stress and fatigue.
Kush Bottles Inc. (OTCQB: KSHB) provides packaging products and solutions to producers, processors and retailers operating in the regulated medical and recreational cannabis industry. The company recently revealed that it has added two new distribution partners in Hawaii and Puerto Rico, two key medical cannabis markets. The move will significantly enhance the company's ability to attract and service new customers in these emerging markets. The company's Hawaii distribution partner will service the island's dispensaries that provide products to registered patients. Hawaii's reciprocity program will also allow sales to patients with valid medical marijuana cards who are visiting from other states. According to the Hawaii Department of Business, Economic Development and Tourism, Hawaii had approximately 9 million tourists visit in 2016.
Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) is a clinical stage pharmaceutical company focused on the development and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. The company's lead product candidate, JBT-101, is a novel synthetic oral endocannabinoid-mimetic drug designed to resolve chronic inflammation, and fibrotic processes. In December, 2016, the company announced that it has completed its Phase 2 study evaluating JBT-101 ("Resunab") for the treatment of cystic fibrosis ("CF").
Please SIGN UP NOW at http://www.FinancialBuzz.com To Receive Alerts on Trending Financial News from all these companies. "The Latest Buzz in Financial News"
Subscribe Now! Watch us report from NYSE https://www.youtube.com/FinancialBuzzMedia
Follow us on Twitter for real time Financial News Updates: https://twitter.com/financialbuzz
Follow and talk to us on Instagram: https://www.instagram.com/financialbuzz
Facebook Like Us to receive live feeds: https://www.facebook.com/Financialbuzz/
FinancialBuzz.com, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, FinancialBuzz.com creates 100% unique original content. FinancialBuzz.com also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.
For further information:
Media Contact: firstname.lastname@example.org , +1-877-601-1879